Study of Polymorphisms of RAAS and MMPs in Acute Heart Failure

Study of Polymorphisms of Renin Angiotensin Aldosteron Systemv(RAAS) and Matrice Metallo Protesase (MMPs) in Acute Heart Failure (AHF)

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT02170961

Acronym

PRA-MMP

Enrollment

300

Registered

2014-06-23

Start date

2013-02-28

Completion date

2016-12-31

Last updated

2020-08-11

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Acute Heart Failure

Keywords

Acute heart failure, RAAS, MMP3, MMP12, Polymorphysm

Brief summary

this study aim to investigate the: * association of RAAS polymorphisms and AHF * association of MMP 3 and 12 polymorphisms and AHF

Detailed description

Heart failure can be defined as a complex clinical syndrome that results from any structural or functional disorder of the heart, with impairment of ability to fill the ventricles or eject blood. The main event of the IC is dyspnea and fatigue, which limit exercise tolerance and induces water retention. The renin angiotensin aldosterone system governs the salt and water homeostasis in the body. Renin is a proteolytic enzyme secreted by the juxtaglomerular apparatus of the kidney (area near the glomeruli). Renin has no direct action on the organism, but that is part of the renin-angiotensin system or the renin-angiotensin-aldosterone system is known. To date, few published studies have examined the association between the polymorphism AGT M235T \* and cardiac dysfunction; and available results are contradictory. What is not known yet is the ratio of this polymorphism with the prognosis of heart failure.

Interventions

None listed

Study design

Observational model

COHORT

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

* aged more than 18 year old. * acute non traumatic dyspnea .

Exclusion criteria

* ECG diagnostic for acute myocardial infarction or ischemic chest pain within the prior 24 hours * a history of a heart transplant, pericardial effusion, chest wall deformity suspected of causing dyspnea * coma, shock,MV,vasopressor drugs * arrhythmia serious and sustained, * pace maker * severe mitral valve disease,

Design outcomes

Primary

Measure	Time frame	Description
mortality RAAS	one year	the association between RAAS genes polymorphisms and mortality at one year average

Secondary

Measure	Time frame	Description
association between RAAS polymorphism and AHF	at admission (an average of 1 day)	the association between the diagnosis of AHF (based on clinical, BNP, and echocardiographic finds) and the RAAS genes polymorphism is studied at patient admission for acute dyspnea.
association between MMP polymorphism and AHF	at admission (average of 1 day)	the association between the diagnosis of AHF (based on clinical, BNP, and echocardiographic finds) and the MMP genes polymorphism is studied at patient admission for acute dyspnea.

Countries

Tunisia

Outcome results